Filing Flows › Bicycle Therapeutics (BCYC) › R&D spending
Bicycle Therapeutics (BCYC) R&D spending by quarter
Bicycle Therapeutics' R&D spending was $33.4M in Q3 2026 (third quarter 2026), -19% from Q2 2026. Over the last 7 quarters it ranged from $33.4M (Q3 2026) to $71.0M (Q2 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $33.4M | -19% | -43% |
| Q2 2026 | $41.2M | -16% | -42% |
| Q1 2026 | $48.9M | -6% | -17% |
| Q4 2025 | $51.8M | -11% | — |
| Q3 2025 | $58.4M | -18% | — |
| Q2 2025 | $71.0M | +20% | — |
| Q1 2025 | $59.1M | — | — |
Q3 2026 at a glance
Bicycle Therapeutics, Q3 2026: revenue $34.1M (+190% year over year), operating margin -39.6%, net loss $10.5M, operating cash flow −$40.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is Bicycle Therapeutics' R&D spending?
Bicycle Therapeutics' R&D spending was $33.4M in Q3 2026 (third quarter 2026), -19% from Q2 2026.
How has Bicycle Therapeutics' R&D spending changed?
Over the last 7 quarters it ranged from $33.4M (Q3 2026) to $71.0M (Q2 2025).